Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for deucravacitinib

  1. Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)

    Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    28 June 2023
    View recommendations

    Sections for TA907

  2. Spesolimab for treating generalised pustular psoriasis flares [ID3963]

    In development [GID-TA10871] Expected publication date: 19 March 2025

    Technology appraisal guidance
    In development

  3. Deucravacitinib for treating active psoriatic arthritis TS ID 11981

    Awaiting development [GID-TA11510] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development